BMI and BMI change following incident type 2 diabetes and risk of microvascular and macrovascular complications: the EPIC-Potsdam study.

Elli Polemiti, Julia Baudry, Olga Kuxhaus, Susanne Jäger, Manuela M Bergmann, Cornelia Weikert, Matthias B Schulze
Author Information
  1. Elli Polemiti: Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany. ORCID
  2. Julia Baudry: Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany. ORCID
  3. Olga Kuxhaus: Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany.
  4. Susanne Jäger: Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany. ORCID
  5. Manuela M Bergmann: Human Study Center, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany. ORCID
  6. Cornelia Weikert: German Federal Institute for Risk Assessment, Department of Food Safety, Berlin, Germany. ORCID
  7. Matthias B Schulze: Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, Germany. mschulze@dife.de.

Abstract

AIMS/HYPOTHESIS: Studies suggest decreased mortality risk among people who are overweight or obese compared with individuals with normal weight in type 2 diabetes (obesity paradox). However, the relationship between body weight or weight change and microvascular vs macrovascular complications of type 2 diabetes remains unresolved. We investigated the association between BMI and BMI change with long-term risk of microvascular and macrovascular complications in type 2 diabetes in a prospective cohort study.
METHODS: We studied participants with incident type 2 diabetes from the European Prospective Investigation into cancer and Nutrition (EPIC)-Potsdam cohort, who were free of cancer, cardiovascular disease and microvascular disease at diagnosis (n = 1083). Pre-diagnosis BMI and relative annual change between pre- and post-diagnosis BMI were evaluated in multivariable-adjusted Cox models.
RESULTS: There were 85 macrovascular (myocardial infarction and stroke) and 347 microvascular events (kidney disease, neuropathy and retinopathy) over a median follow-up of 10.8 years. Median pre-diagnosis BMI was 29.9 kg/m (IQR 27.4-33.2), and the median relative annual BMI change was -0.4% (IQR -2.1 to 0.9). Higher pre-diagnosis BMI was positively associated with total microvascular complications (multivariable-adjusted HR per 5 kg/m [95% CI]: 1.21 [1.07, 1.36], kidney disease 1.39 [1.21, 1.60] and neuropathy 1.12 [0.96, 1.31]) but not with macrovascular complications (HR 1.05 [95% CI 0.81, 1.36]). Analyses according to BMI categories corroborated these findings. Effect modification was not evident by sex, smoking status or age groups. In analyses according to BMI change categories, BMI loss of more than 1% indicated a decreased risk of total microvascular complications (HR 0.62 [95% CI 0.47, 0.80]), kidney disease (HR 0.57 [95% CI 0.40, 0.81]) and neuropathy (HR 0.73 [95% CI 0.52, 1.03]), compared with participants with a stable BMI; no clear association was observed for macrovascular complications (HR 1.04 [95% CI 0.62, 1.74]). The associations between BMI gain compared with stable BMI and diabetes-related vascular complications were less apparent. Associations were consistent across strata of sex, age, pre-diagnosis BMI or medication but appeared to be stronger among never-smokers compared with current or former smokers.
CONCLUSIONS/INTERPRETATION: Among people with incident type 2 diabetes, pre-diagnosis BMI was positively associated with microvascular complications, while a reduced risk was observed with weight loss when compared with stable weight. The relationships with macrovascular disease were less clear.

Keywords

References

  1. N Engl J Med. 2014 Jan 16;370(3):233-44 [PMID: 24428469]
  2. J Am Geriatr Soc. 2014 Oct;62(10):2002-4 [PMID: 25333547]
  3. Diabetes Metab Res Rev. 2015 Feb;31(2):138-46 [PMID: 25044633]
  4. Acta Diabetol. 2019 Jan;56(1):87-96 [PMID: 30167871]
  5. Stroke. 2015 Jan;46(1):164-9 [PMID: 25468880]
  6. J Nephrol. 2012 May-Jun;25(3):384-93 [PMID: 22241634]
  7. Lancet. 2018 Feb 10;391(10120):541-551 [PMID: 29221645]
  8. J Acad Nutr Diet. 2015 Sep;115(9):1447-63 [PMID: 25935570]
  9. Medicine (Baltimore). 2014 Aug;93(7):e41 [PMID: 25101985]
  10. South Med J. 2015 Jan;108(1):29-36 [PMID: 25580754]
  11. Diabetes Care. 2019 Feb;42(2):240-247 [PMID: 30523031]
  12. N Engl J Med. 2013 Jul 11;369(2):145-54 [PMID: 23796131]
  13. Diabetologia. 2009 Jan;52(1):65-73 [PMID: 18985314]
  14. Nutr Metab Cardiovasc Dis. 2010 Feb;20(2):110-6 [PMID: 19447588]
  15. Endocrine. 2019 Apr;64(1):82-89 [PMID: 30864142]
  16. Ann Nutr Metab. 1999;43(4):216-24 [PMID: 10592370]
  17. BMC Med. 2018 Jun 27;16(1):99 [PMID: 29945632]
  18. Sci Rep. 2017 Aug 1;7(1):7041 [PMID: 28765572]
  19. Diabetes Obes Metab. 2014 Apr;16(4):317-25 [PMID: 24118783]
  20. Stat Med. 2011 Feb 20;30(4):377-99 [PMID: 21225900]
  21. J Am Heart Assoc. 2018 Nov 20;7(22):e010512 [PMID: 30554548]
  22. Diabetologia. 2017 Feb;60(2):240-248 [PMID: 27888288]
  23. J Diabetes. 2017 Nov;9(11):983-993 [PMID: 27976508]
  24. Ann Nutr Metab. 1999;43(4):205-15 [PMID: 10592369]
  25. Diabetes Care. 2006 Jun;29(6):1294-9 [PMID: 16732011]
  26. Arch Intern Med. 1997 Mar 24;157(6):650-6 [PMID: 9080919]
  27. Am J Clin Nutr. 1999 Oct;70(4):439-47 [PMID: 10500011]
  28. Front Neurol. 2019 Jun 05;10:563 [PMID: 31231300]
  29. J Diabetes Complications. 2016 Jul;30(5):790-7 [PMID: 26997170]
  30. Am J Lifestyle Med. 2016 May 19;12(3):244-251 [PMID: 30202394]
  31. Ann Intern Med. 2015 May 5;162(9):610-8 [PMID: 25938991]
  32. Diabetes Care. 2020 Jan;43(Suppl 1):S89-S97 [PMID: 31862751]
  33. J Diabetes Investig. 2018 Jan;9(1):44-54 [PMID: 28593750]
  34. BMJ Open. 2016 Jul 26;6(7):e010836 [PMID: 27466237]
  35. PLoS One. 2016 Jan 25;11(1):e0146889 [PMID: 26808532]
  36. Diabetes Res Clin Pract. 2019 Sep;155:107807 [PMID: 31394129]
  37. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253 [PMID: 11234459]
  38. Diabetologia. 2019 Aug;62(8):1391-1402 [PMID: 31062041]
  39. Diabetes Obes Metab. 2019 Oct;21(10):2338-2341 [PMID: 31207010]
  40. Lancet Diabetes Endocrinol. 2016 Nov;4(11):913-921 [PMID: 27595918]
  41. Ann Nutr Metab. 1999;43(4):225-34 [PMID: 10592371]

MeSH Term

Adult
Body Mass Index
Diabetes Mellitus, Type 2
Diabetic Angiopathies
Female
Germany
Humans
Incidence
Male
Middle Aged
Obesity
Prognosis
Prospective Studies
Protective Factors
Risk Assessment
Risk Factors
Time Factors
Weight Gain
Weight Loss

Word Cloud

Created with Highcharts 10.0.0BMI10complicationsmicrovascular2changemacrovasculartypediabetesdiseaseHR[95%riskcomparedweightCIpre-diagnosisincidentkidneyneuropathystabledecreasedamongpeopleassociationcohortstudyparticipantsrelativeannualmultivariable-adjustedmedianIQRpositivelyassociatedtotal21[136]accordingcategoriessexageloss62clearobservedvascularlessAIMS/HYPOTHESIS:StudiessuggestmortalityoverweightobeseindividualsnormalobesityparadoxHoweverrelationshipbodyvsremainsunresolvedinvestigatedlong-termprospectiveMETHODS:studiedEuropeanProspectiveInvestigationCancerNutritionEPIC-Potsdamfreecancercardiovasculardiagnosisn = 1083Pre-diagnosispre-post-diagnosisevaluatedCoxmodelsRESULTS:85myocardialinfarctionstroke347eventsretinopathyfollow-up108 yearsMedian299 kg/m274-33-04%-29Higherper5 kg/mCI]:073960]12[09631]0581AnalysescorroboratedfindingsEffectmodificationevidentsmokingstatusgroupsanalyses1%indicated4780]574081]735203]0474]associationsgaindiabetes-relatedapparentAssociationsconsistentacrossstratamedicationappearedstrongernever-smokerscurrentformersmokersCONCLUSIONS/INTERPRETATION:Amongreducedrelationshipsfollowingcomplications:EPIC-PotsdamCVDDiabetes-relatedNephropathyNeuropathyT2DWeight

Similar Articles

Cited By (26)